Arenavirus Infection Lassa Fever Therapeutics Pipeline Review, H1 2015 - 2 Companies & 8 Drug Profiles
M2 - Tue Jun 09, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rlzl2x/arenavirus) has announced the addition of the "Arenavirus Infection Lassa Fever - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Arenavirus Infection Lassa Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arenavirus Infection Lassa Fever and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Profectus BioSciences, Inc. - SIGA Technologies, Inc. Drug Profiles - EMER-IT - lassa fever vaccine - lassa fever vaccine 1 - lassa fever vaccine 2 - Monoclonal Antibodies for Viral Infections - Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus - ST-161 - ST-193 For more information visit http://www.researchandmarkets.com/research/rlzl2x/arenavirus
Poxvirus Infections Pipeline Report 2015 - 4 Companies & 10 Drug Profiles
M2 - Thu May 21, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q5d6dv/poxvirus) has announced the addition of the "Poxvirus Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Poxvirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Poxvirus Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - BioApex, s.r.o. - China Biologic Products, Inc. - SIGA Technologies, Inc. - Takeda Pharmaceutical Company Limited Drug Profiles - 4-ThioIDU - Antibody for Poxvirus Infections - BA-368 - modified vaccinia ankara vaccine - Monoclonal Antibodies for Vaccinia Infection - Small Molecule to Inhibit DNA Synthesis for Viral Infections - Small Molecules to Inhibit Viral DNA Polymerase for Herpes and Poxvirus Infections - Small Molecules to Target Heparan Sulphate Proteoglycan for Bacterial and Viral Infections - tecovirimat - varicella hyperimmune globulins For more information visit http://www.researchandmarkets.com/research/q5d6dv/poxvirus
CBPO: 111.03 (+7.77)
Delisting of Securities of Life Partners Holdings Inc., SIGA Technologies, Inc., Exceed Company Ltd., Video Display Corporation, and Home Loan Servicing Solutions, Ltd. From The NASDAQ Stock Market
GlobeNewswire - Wed May 20, 3:05PM CDT
The NASDAQ Stock Market announced today that it will delist the common stock of Life Partners Holdings Inc. Life Partners Holdings Inc.'s stock was suspended on March 30, 2015 and has not traded on NASDAQ since that time.
NDAQ: 50.48 (+1.26)